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Abstract: Active compounds from natural products have been widely studied. The 
anti-tumor effects of 13-acetoxysarcocrassolide isolated from Formosan soft coral 
Sarcophyton crassocaule on bladder cancer cells were examined in this study. An MTT 
assay showed that 13-acetoxysarcocrassolide was cytotoxic to bladder female transitional 
cancer (BFTC) cells. We determined that the BFTC cells underwent cell death through 
apoptosis by flow cytometry. Due to the highly-migratory nature of the BFTC cells, the 
ability of 13-acetoxysarcocrassolide to stop their migration was assessed by a wound 
healing assay. To determine which proteins were affected in the BFTC cells upon treatment, 
a comparative proteomic analysis was performed. By LC-MS/MS analysis, we identified 
that 19 proteins were up-regulated and eight were down-regulated. Seven of the proteins 
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were confirmed by western blotting analysis. This study reveals clues to the potential 
mechanism of the cytotoxic effects of 13-acetoxysarcocrassolide on BFTC cells. Moreover, it 
suggests that PPT1 and hnRNP F could be new biomarkers for bladder cancer. The results 
of this study are also helpful for the diagnosis, progression monitoring and therapeutic 
strategies of transitional cell tumors. 
Keywords: 13-acetoxysarcocrassolide; Sarcophyton crassocaule; BFTC cells; 
proteomic analysis 
 
1. Introduction 
Urothelial carcinomas are the fourth most common tumors after prostate (or breast) cancer, lung 
cancer, and colorectal cancer. Bladder tumors account for 90–95% of urothelial carcinomas. It has 
been estimated that approximately 90% of human bladder tumors are present as transitional cell  
tumors [1,2]. Transitional cell tumors have high incidence in adults and are a common cause of death 
of genitourinary tumors [3,4], which explains why transitional cell carcinoma in the elderly population 
is becoming increasingly important [5]. It has also been reported that the percentage of female patients 
with cancer rises with increasing age [6]. Typical characteristics of transitional cell tumors are their 
multifocal origin and high recurrence-rate (about 60%–70%) after transurethral resection. Some agents 
like mitomycin C and adriamycin have been used for intravesical chemotherapy. This treatment has 
diminished the early recurrence-rate in about 14% of patients. Intravesical bacille Calmette-Guérin 
(BCG) has been reported to have the greatest effects with the highest response rate on transitional cell 
carcinoma despite its frequent side effects [7,8]. It is essential to find new diagnosis and treatment 
measures for superficial transitional cell carcinoma.   
The therapeutic applications of natural products isolated from soft corals have been widely 
investigated [9–11]. Several steroid compounds such as diterphenoids, diterpenes, and prostanoids have 
been isolated from marine soft corals. These types of compounds have been reported to induce apoptosis 
and are cytotoxic against different cancer cell lines, such as prostate, breast, colon, cervical, liver, and  
oral cancer cell lines [12–17]. Three diterpenoids, 1-epi-leptocladolide A, leptocladolides A, and 
7E-leptocladolide A isolated from the Taiwanese soft coral Sinularia parva were found to have 
significant cytotoxic effects against KB and Hepa59T/VGH cancer lines [18]. Reports on activities of 
compounds from natural products on human bladder cancer cells are very limited. Bladder female 
transitional cancer (BFTC) cells have been widely used in biomedical and urological studies of bladder 
tumors [4,19,20]. In previous studies a series of novel secondary metabolites, including cembranes [21–33], 
steroids [22,28,30], hippurins [31], prostaglandins [32] and others [33] have been isolated from the 
Formosan soft coral Sarcophyton crassocaule. Some of these have been found to possess several kinds 
of biological activities, such as cytotoxic [22,24,25,27,28] and anti-inflammatory activity [27,28]. In 
the current study, the cytotoxic effects of a cembrenolide diterpene, 13-acetoxysarcocrassolide (Figure 1), 
isolated from Sarcophyton crassocaule on BFTC cells have been examined. Proteomic and western 
blotting analysis was carried out to investigate and confirm the changes of protein expression in BFTC Mar. Drugs 2011, 9 2624 
 
cells after 13-acetoxysarcocrassolide treatment. The data in this study provide information for 
understanding the biochemical aspects of the cytotoxic effects of 13-acetoxysarcocrassolide on BFTC 
cells and will help to develop tools for diagnosis and progression monitoring of transitional cell tumors. 
Figure 1. Chemical structure of 13-acetoxysarcocrassolide. 
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2 Materials and Methods 
2.1. Materials 
Cell Extraction Buffer was obtained from BioSource International (Camarillo, CA, USA). Protease 
inhibitor cocktail was from Sigma (St Louis, MO, USA). The IPG buffer (pH 4–7) for two-dimensional 
gel electrophoresis (2-DE) was purchased from GE Healthcare (Buckinghamshire, UK). Rabbit 
anti-human heat shock protein 60 (HSP60), isocitrate dehydrogenase (IDH), Stress-70 protein, heat 
shock cognate 71 kDa protein (HSC71), heterogeneous nuclear ribonucleoproteins F (hnRNP F), 
heterogeneous nuclear ribonucleoproteins C1/C2 (hnRNP C1/C2) and protein disulfide-isomerase A3 
(PDIA3) antibodies were obtained from ProteinTech Group (Chicago, IL, USA). Antibodies against 
caspase-3, cleaved caspase-3, caspase-8, caspase-9, cleaved caspase-9 and Bcl-xL were from Cell 
Signaling Technology (Danvers, MA, USA). Antibodies against cytochrome C and p53 were from 
Epitomics (Burlingame, CA, USA). Rabbit anti-human β-actin antibodies were obtained from Sigma. 
Goat anti-rabbit and horseradish peroxidase conjugated IgG was from Millipore (Bellerica, MA, USA). 
PVDF (Polyvinylidene difluoride) membranes and Chemiliminescent HRP Substrate were from Pierce 
(Rockford, IL, USA).   
2.2. Cell Culture and the Treatment with 13-Acetoxysarcocrassolide 
BFTC cells were cultured in DMEM with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium 
bicarbonate and 4.5 g/L glucose, supplemented with 10% (v/v) FBS, 100 units/mL penicillin,  
100 μg/mL streptomycin, 1 mM sodium pyruvate, and 0.01 mg/mL human transferrin in a humidified 
incubator with 5% CO2 at 37 °C.When cells were above 70% confluent, subculture was conducted at a 
split ratio of 1:6. The isolation of 13-acetoxysarcocrassolide from the soft coral Sinularia leptoclado 
was accomplished according to the reported procedures [34]. Control cultures were prepared by adding 
DMSO at the same final concentration as in the treated samples (0.01% v/v). DMSO was used to 
dissolve 13-acetoxysarcocrassolide. BFTC cells were treated with different concentrations of 
13-acetoxysarcocrassolide (0.5 μg/mL, 1.0 μg/mL, 1.5 μg/mL, 3.0 μg/mL and 5.0 μg/mL) and 
harvested after incubation for 24 h. All the experiments were repeated three times. Mar. Drugs 2011, 9 2625 
 
2.3. MTT Assay 
The anti-proliferative effect of 13-acetoxysarcocrassolide on BFTC cells was measured by MTT 
assay. BFTC cells were seeded at a density of 1 × 10
5/cm
2 in 96 well plates. After the addition of 
0.5–5.0 μg/mL 13-acetoxysarcocrassolide for 24 h, the MTT solution (1 mg/mL in PBS) was added to 
each well. The plates were then incubated at 37 °C for 4 h. DMSO was applied to each well to achieve 
solubility of purple-blue MTT formazan crystals in viable cells. The optimal density (O.D) was 
measured at 595 nm by a microplate ELISA reader with DMSO as the blank. Data were presented as  
±standard error of mean (SEM) of the pooled data. Statistical comparisons of two or more groups of 
data were carried out using one-way analysis of variance (ANOVA) followed by the Tukey-Kramer 
multiple comparison test to determine the significant differences between the experimental groups by 
GraphPad Instat statistical software (San Diego, CA, USA) [35]. 
2.4. Wound-Healing Assay 
The anti-migratory and anti-motility effects of 13-acetoxysarcocrassolide on BFTC cells were 
examined by a wound healing assay. BFTC cells were seeded in 6 well plates 18 h before the addition 
of 13-acetoxysarcocrassolide. An artificial wound was created with a 10 μL pipette tip at 0 h. 
Unattached tumor cells were removed by the wash with PBS. Images of the experimental groups  
(0 μg/mL, 1.0 μg/mL, 1.5 μg/mL and 3.0 μg/mL 13-acetoxysarcocrassolide) were acquired at 0 h, 6 h, 
12 h and 24 h after the treatment of 13-acetoxysarcocrassolide. The images of migrated tumors cells 
inside the wound were acquired by an inverted light microscope with an imaging system (Nikon). 
2.5. Analysis of Cell Cycle and Apoptosis 
Harvested BFTC cells were fixed in ice-cold 70% ethanol at 4 °C for 30 min. After centrifugation, 
the cell pellets were washed and resuspended in PBS. Tumor cells were then treated with ribonuclease 
A (25 mg/L) and 0.5% Triton X-100 at 37 °C for 60 min. Cellular DNA was stained with propidium 
iodide (50 mg/L) for 30 min. After centrifugation, the pellets were resuspended in PBS. The cellular 
DNA in 104 cells was analyzed in Elite-ESP flow cytometer (Beckman Coulter, Miami, FL, USA) and 
fixed with an argon laser set at 488 nm. The percentage of apoptosis was determined by Elite-ESP 
software program (Beckman Coulter, Miami, FL, USA).   
2.6. Protein Extraction and Preparation 
BFTC cells treated with 0, 0.5, 1.0, 1.5, 3.0 and 5.0 μg/mL 13-acetoxysarcocrassolide for 24 h were 
lysed with Cell Extraction Buffer (BioSource International) and protease inhibitor cocktail (Sigma). 
The total protein in the supernatant was then precipitated out by triple the volume of 10% 
TCA/Acetone solution containing 20 mM DTT at −20 °C overnight. The mixture was then centrifuged 
at 8000 rpm for 30 min at 4 °C. The supernatant was discarded. The pellet was suspended in 
rehydration buffer (6 M urea, 2 M thiourea, 0.5% CHAPS, 0.5% IPG buffer, 20 mM DTT, and 0.002% 
bromophenol blue) at 4 °C for overnight. The protein contents were determined using 2-D Quant Kit 
(GE Healthcare). Mar. Drugs 2011, 9 2626 
 
2.7. Two-Dimensional Gel Electrophoresis 
The first dimension electrophoresis (isoelectric focusing) was performed with GE Healthcare Ettan 
IPGphor 3 using the reported procedure [36]. Proteins (50 μg) extracted from whole cell were loaded 
on 11-cm strip. Every 11-cm IPG strip (pI 4–7, Immobiline DryStrip) was rehydrated at 30 V for 12 h 
and then focused according to the preset program: 200 V (2 h), 500 V (2 h), 1000 V (2 h), 4000 V (1 h), 
8000 V (4 h), until the total Vh reached 39,400. The equilibrated strip was placed on the top of a 
SDS-PAGE gel (12.5%) and then the second dimension electrophoresis was run at 150 V for 6.5 h. The 
2-DE gels were stained with silver staining and then subjected to image analysis with the PDQuest 2-D 
software (version 7.1.1). 2-DE images were taken in triplicate for each sample and normalized prior to 
statistical analysis.   
2.8. Protein Identification by LC-MS/MS 
The protein spots of interest were excised, destained and then subjected to tryptic in-gel digestion as 
described in a previous report [37]. MS analysis was performed using a AB SCIEX QTRAP
® 5500Q 
mass spectrometer (Applied Biosystems, CA, USA). A peptide mixture was separated by nanoflow 
reversed phase C18 chromatography on nano LC using the Agilent 1200 System and PepMap100 C18, 
75 μm × 15 cm (3 μm) nanoLC column or HPLC using the Agilent NanoLC 1200 System and Agilent 
Zobax 2.1 mm × 150 mm C18 column. LC-MS/MS analysis employed a 10-min online trapping and 
desalting step followed by a 60-min 5–40% mobile phase B gradient at nano flow and a 15-min 5–40% 
mobile B phase gradient at higher flow (mobile phase B = 98% ACN, 0.1% formic acid). The scan 
range was from m/z 100 to 1000 for MS. The raw data was processed into a text file format of  
WIFF with Analyst 1.5.1. MASCOT was used in searching for protein identification by NCBInr 
protein database. 
2.9. Western Blot Analysis 
Western blotting was conducted to verify the regulation of 7 differential 2-DE-detected proteins and 
changes of the pro-apoptotic factors correlated with HSP60 and hnRNP F. The protein samples under 
reducing conditions were separated by 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE). The 
proteins on the gel were then transferred to PVDF membranes. The membranes were incubated with 
rabbit polyclonal antibodies against human HSP60, stress-70 protein, HSC71, IDH, hnRNP C1/C2, 
hnRNP F, PDIA3, caspase-3, cleaved caspase-3, caspase-8, caspase-9, cleaved caspase-9, p53, 
cytochrome C, Bcl-xL and β-actin at 4 °C for 2 h or overnight. The membranes were washed three 
times in PBST (10 mM NaH2PO4, 130 mM NaCl, 0.05% Tween 20), then incubated with the second 
antibodies (goat anti-rabbit and horseradish peroxidase conjugate, 1:5000 in blocking solution) for 1 h. 
After washing with PBST for three times, the blots were visualized through chemiluminesence by 
adding ECL western blotting reagents on the Alpha Innotech System (San Leandro, CA, USA). Mar. Drugs 2011, 9 2627 
 
3 Results 
3.1. The Anti-Proliferative Effect of 13-Acetoxysarcocrassolide on BFTC Cells 
The anti-proliferative effect of 13-acetoxysarcocrassolide was measured by the colorimetric 
MTT  assay. The concentration of 13-acetoxysarcocrassolide ranging from 0.5 μg/mL to 5 μg/mL 
dose-dependently inhibited the growth of BFTC cells (P < 0.01 and P < 0.001, Figure 2). Under the 
observation of inverted light microscopy, the population of BFTC cells was clearly reduced after 
treatment with 1.5 and 3 μg/mL (Figure 3). 
Figure 2. Viability of bladder female transitional cancer (BFTC) cells exposed to increasing 
concentrations of 13-acetoxysarcocrassolide. 13-acetoxysarcocrassolide dose-dependently 
suppressed the growth of BFTC cells (
# P < 0.01 and * P < 0.001). Inhibitory effects on 
cell proliferation were assessed by MTT assay as described in Materials and Methods. Data 
were presented with the mean ± SEM from three independent experiments. 
 
Figure 3. Decreased population and morphological changes of BFTC cells treated with 
different concentrations of 13-acetoxysarcocrassolide for 24 h. (A) control; (B) 1 μg/mL; 
(C) 1.5 μg/mL; and (D) 3 μg/mL of 13-acetoxysarcocrassolide. 
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3.2. The Anti-Migratory Effect of 13-Acetoxysarcocrassolide on BFTC Cells 
The anti-migratory effect of 13-acetoxysarcocrassolide was examined using a wound healing assay. 
The decreased areas of artificial wounds were observed after treatment with 13-acetoxysarcocrassolide. 
BFTC cell migration was reduced with increasing concentrations and exposure time of 
13-acetoxysarcocrassolide. The experiments were repeated three times and migrated BFTC cells inside 
the wound were significantly reduced at 12 and 24 h after exposure to 1, 1.5 and 3 μg 
13-acetoxysarcocrassolide (* P < 0.001) (Figure 4 and Table 1).   
Figure 4. Wound healing assay of BFTC cells treated with increasing concentrations of 
13-acetoxysarcocrassolide. Cells in the areas between the two solid lines were those 
migrated in the gaps during the indicated time periods. It was seen that increased 
13-acetoxysarcocrassolide concentration decreased the migration ability of BFTC cells.   
0hr 24hr 12hr 6hr
control
3.0 μg/ml
1.5 μg/ml
1.0 μg/ml
 
Table 1. BFTC cells were exposed to increasing concentrations of 13-acetoxysarcocrassolide. 
Migrated BFTC cells inside the wound were counted after the indicated time periods. The 
data of cell count are from three individual assays and analyzed using ANOVA followed by 
the Tukey-Kramer multiple comparisons test and presented as mean ± SEM (* P < 0.001). 
  0 h  6 h  12 h  24 h 
control  8.333 ± 3.215  46 ± 8  158.67 ± 18.175  344 ± 14.177 
1 μg 
13-acetoxysarcocrassolide 
10.67 ± 3.512  17.67 ± 6.506 107.31 ± 5.275 *  219.67 ± 21.197 *
1.5 μg 
13-acetoxysarcocrassolide 
5.33 ± 2.309  14 ± 5  79 ± 10.44 *  155.33 ± 12.22 * 
3 μg 
13-acetoxysarcocrassolide 
4.67 ± 3.055  11.33 ± 5.508 53.33 ± 15.503 *  105.33 ± 12.662 *Mar. Drugs 2011, 9 2629 
 
3.3. Apoptosis-Induced Effects of 13-Acetoxysarcocrassolide on BFTC Cells 
The BFTC cells with or without 13-acetoxysarcocrassolide treatment were harvested and stained 
with propidium iodine. Tumor cells marked at sub-G1 phase were measured as apoptotic BFTC cells. 
The apoptotic rate of BFTC cells was doubled by the treatment of either 1 or 1.5 μg/mL of 
13-acetoxysarcocrassolide in comparison with the control (* P < 0.001, Figure 5). There is no 
statistical difference in the apoptotic rate between the effects of the treatments of 1 and 1.5 μg/mL 
13-acetoxysarcocrassolide (Figure 5). 
Figure 5. ( A) Flow cytometric analysis represented by PI staining for the 
apoptosis-induced effects of 13-acetoxysarcocrassolide on BFTC cells. BFTC cells were 
exposed to 13-acetoxysarcocrassolide at 0, 1 and 1.5 μg/mL for 24 h, and then collected 
and stained as described in Materials and Methods. Cells at sub-G1 phase were assessed as 
apoptotic cells; (B) 13-acetoxysarcocrassolide at 1 and 1.5 μg/mL doubled the apoptotic 
rate compared with that of the control (* P < 0.001). Data were pooled from three 
independent runs and analyzed by ANOVA followed by the Tukey-Kramer multiple 
comparison test. 
6.50% 14.45% 14.69%
A
B
0.5 μg/ml 1.0 μg/ml 1.5 μg/ml
6.50% 6.50% 14.45% 14.45% 14.69% 14.69%
A
B
0.5 μg/ml 1.0 μg/ml 1.5 μg/ml
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3.4. Proteomic Analysis of BFTC Cells Treated with 13-Acetoxysarcocrassolide 
BFTC cells were harvested after being treated with 1.5 μg/mL 13-acetoxysarcocrassolide. The 
proteins from the cells were extracted and the supernatants were collected. Proteins were precipitated 
by TCA/Acetone. The 2-DE maps of BFTC cells treated with 13-acetoxysarcocrassolide were 
compared with those of the control to analyze the effect of 13-acetoxysarcocrassolide on BFTC cells. 
The 2-DE was completed with a loading of 50 μg protein (pI 4–7) and visualized by silver staining 
(Figure 6). PDQuest image analysis software (Bio-Rad, CA, USA) was employed to detect the 
differential protein spots which were defined as the proteins showing a more than 1.5 fold intensity 
difference in 2-DE maps between the treated BFTC cells and the control. The protein identification 
was carried out by LC-MS/MS analysis after in gel digestion. MASCOT protein identification search 
software was used for the identification of the differential protein spots. A total of 27 differential 
protein spots were successfully identified. A list of the identified proteins with their MASCOT score, 
MS/MS matched sequences, apparent and theoretical MW, pI, coverage, and folds of change in 
expression level (up-regulation or down-regulation) are shown in Table 2.   
Figure 6. The 2-DE maps of BFTC cells treated with 13-acetoxysarcocrassolide and the 
control sample. (A) control; (B) treated with 1.5 μg/mL 13-acetoxysarcocrassolide for 24 h. 
Proteins spots marked on the maps were considered differentially expressed and identified 
by LC-MS/MS. The results are representative of three independent runs.   
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Table 2. A total of 27 differential proteins and their changes identified by LC-MS/MS after 
treatment with 1.5 μg/mL 13-acetoxysarcocrassolide for 24 h. 
Spot 
no. 
Protein name  Accession
no. 
Calculate 
Mr/pI 
Peptide 
matched
Sequence 
covered % 
MASCO
T score 
Regulation 
(fold-change) *
1 Heterogeneous  nuclear  ribonucleoproteins 
C1/C2 
P07910 33.65/4.95 10  21  99  +7.0 
2 Heterogeneous  nuclear  ribonucleoproteins 
C1/C2 
P07910 33.65/4.95 14  35  163  +8.3 
3 Heterogeneous  nuclear 
ribonucleoprotein F 
P52597 45.64/5.38 20  31  201  +2.0 
4  Heat shock cognate 71 kDa protein  P11142  70.85/5.37 7  14  93  +3.7 
5  60 kDa heat shock protein  P10809  61.01/5.7  35  39  686  −2.0 
6 Stress-70  protein  P38646  73.63/5.87 27  37  333  +2.2 
7 Arginase-2  P78540  38.55/6.0  2  8  70  +2.0 
8  Protein disulfide-isomerase A3 precursor  P30101  54.74/5.98 26  41  387  −2.3 
9  L-lactate dehydrogenase B chain  P07195  36.61/5.71 7  16  63  +2.6 
10 Isocitrate  dehydrogenase  [NAD] 
subunit alpha 
P50213 39.56/6.47 7  15  127  −3.2 
11  Protein disulfide-isomerase A3 precursor  P30101  54.74/5.98 14  29  211  −1.8 
12 Mitochondrial-processing peptidase 
subunit beta 
O75439 54.33/6.38 11  23  126  +2.8 
13 Heterogeneous  nuclear  ribonucleoprotein 
H3 (hnRNP H3) 
P31942 36.9/6.37  3  10  74  −2.1 
14  Palmitoyl-protein thioesterase 1 precursor  P50897  34.17/6.07 5  10  83  +1.8 
15  Proteasome subunit beta type 4 precursor  P28070  29.18/5.72 6  24  92  −3.0 
16  Thioredoxin domain-containing protein 5 
precursor 
Q8NBS9 47.59/5.63 4  11  69  +2.2 
17 Dihydrolipoyllysine-residue 
acetyltransferase component of pyruvate 
dehydrogenase complex 
P10515 65.73/5.79 5  2  63  −2.0 
18 Protein  NDRG1  Q92597  42.8/5.49  9  25  129  +2.3 
19 Ubiquinol-cytochrome-c  reductase 
complex core protein 1 
P31930 52.61/5.94 9  15  156  +2.3 
20 Ubiquinol-cytochrome-c  reductase 
complex core protein 1 
P31930 52.61/5.94 2  3  67  +2.2 
21 Ornithine  aminotransferase  P04181  48.5/6.57  23  30  296  +1.5 
22 Guanine  nucleotide-binding  protein 
G(I)/G(S)/G(T) 
P62873 37.35/5.6  12  20  151  +1.9 
23 Stress-70  protein  P38646  73.63/5.87 17  21  190  +2.7 
24  Heat shock cognate 71 kDa protein  P11142  70.85/5.37 14  17  137  +2.2 
25 Calreticulin  precursor  P27797  48.11/4.29  13  17  99  −3.2 
26  ATP synthase subunit beta  P06576  56.52/5.26 20  34  256  +2.8 
27  Glial fibrillary acidic protein  P14136  49.85/5.42 3  4  53  +2.4 
* Regulations (fold-changes) of differentially expression proteins are expressed at 24 h treatment of 13-acetoxysarcocrassolide. Mar. Drugs 2011, 9 2632 
 
The varied expression of proteins distributed throughout the entire gels indicated that multiple 
clusters of proteins were involved in the effects of 13-acetoxysarcocrassolide on BFTC cells. A total of 
19 differential proteins were up-regulated after 13-acetoxysarcocrassolide treatment. These proteins 
were heterogeneous nuclear ribonucleoproteins C1/C2, heterogeneous nuclear ribonucleoprotein F, 
heat shock cognate 71 kDa protein, stress-70 protein, L-lactate dehydrogenase B chain, 
mitochondrial-processing peptidase subunit beta, palmitoyl-protein thioesterase 1 precursor, thioredoxin 
domain-containing protein 5 precursor, protein NDRG1, ubiquinol-cytochrome-c reductase complex 
core protein 1, ornithine aminotransferase, guanine nucleotide-binding protein G(I)/G(S)/G(T), ATP 
synthase subunit beta, and glial fibrillary acidic protein. In contrast, eight down-regulated proteins 
were 60 kDa heat shock protein, protein disulfide-isomerase A3 precursor, isocitrate dehydrogenase 
[NAD] subunit alpha, heterogeneous nuclear ribonucleoprotein H3, proteasome subunit beta type 4 
precursor, dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase 
complex, and calreticulin precursor.   
3.5. Western Blot Analysis 
The varied expression of HSP60, Stress-70 protein, HSC71, hnRNP C1/C2, hnRNP F, PDIA3, and 
IDH was further verified by western blotting analysis (Figure 7). The results were in accordance with 
the 2-DE data. Modulation of caspase-3 and caspase-9 after the treatment in BFTC cells was also 
determined by western blotting analysis. The elevated expression of cytochrome C, p53, cleaved 
caspase-3, cleaved caspase-9 and a decrease of caspase-3, caspase-9, Bcl-xL in BFTC cells with 
13-acetoxysarcocrassolide treatment were observed (Figure 8). Cleaved caspase-8 was not detected in 
13-acetoxysarcocrassolide-treated cells and the control (data not shown).  Each western blotting 
analysis is repeated three times and a representative result was exhibited. 
Figure 7. Western blotting analysis of HSP60, stress 70 protein, HSC71, PDIA3, hnRNP F, 
hnRNP C1/C2, and IDH in BFTC cells treated with increasing concentrations of 
13-acetoxysarcocrassolide for 24 h. β-actin was used as the internal control. 
HSP60
Stress-70 protein 
IDH
PDIA3
β-actin
hnRNP C1/C2
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Figure 8. Western blotting analysis of caspase-3, cleaved caspase-3, caspase-9, cleaved 
caspase-9, cytochrome C, p53 and Bcl-xL in BFTC cells treated with increasing 
concentrations of 13-acetoxysarcocrassolide for 24 h. β-actin was used as the internal control. 
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4. Discussion 
In the current study, the cembranoid 13-acetoxysarcocrassolide, isolated from the Formosan soft 
coral Sarcophyton crassocaule exerted anti-proliferation, anti-migration and apoptosis-induced effects 
on bladder female transitional cancer (BFTC) cells in vitro. A comparative proteomic analysis was 
then conducted by 2-DE, LC-MS/MS and western blotting analysis to determine the potential 
biomarkers and investigate the induction of cell death in BFTC cells. A total of 27 differential proteins 
have been identified by LC-MS/MS analysis, including 19 up-regulated and 8 down-regulated proteins 
in BFTC cells after exposure to 13-acetoxysarcocrassolide. A Western blot analysis confirmed the 
2-DE data of HSP60, stress-70 protein, HSC71, IDH, hnRNP C1/C2, and hnRNP F. In addition to 
2-fold enhancement of apoptotic BFTC cells after 13-acetoxysarcocrassolide treatment displayed by 
flow cytometry, the regulation of specific proteins like HSP60 and hnRNPs F/H has been shown to be 
associated with pro-apoptotic elements including p53, caspases, involvement of mitochondria and 
Bcl-2 family [38–40]. Hence, we also investigated the changes of cytochrome C, p53, caspase-3, cleaved 
caspase-3, caspase-8, caspase-9, cleaved caspase-9 and Bcl-xL in the 13-acetoxysarcocrassolide-treated 
BFTC cells compared with the control. As a result, up-regulation of cytochrome C, p53, cleaved 
caspase-3 as well as cleaved caspase-9 and down-regulation of Bcl-xL after the treatment with 
13-acetoxysarcocrassolide displayed by western blotting analysis further support the apoptosis-induced 
and anti-proliferative effects of 13-acetoxysarcocrassolide assessed by flow cytometry and MTT assay.   
Caspases are a group of intracellular cysteine proteases involved in the most essential pathways to 
induce apoptosis. Caspase-3, has been indicated to play an important role in nucleosomal DNA 
cleavage and promotion of the caspase activation [41]. Activation of caspase-3 led to apoptosis in Mar. Drugs 2011, 9 2634 
 
breast cancer cells, bladder cancer cells, non-small cell lung cancer cells, neuroblastoma cells, prostate 
cancer cells, gastric cancer cells and cervical cancer cells [42–47]. Another member of the caspase 
family, caspase-9, has also been shown to be associated with the induction of apoptosis in several 
cancer cells including cervical cancer cells, human hepatoma cells, melanoma cells, and human lung 
cancer cells. Interestingly, the activation of caspase-3 is tightly linked to the activation of caspase-9 in 
these anti-tumor studies [48–52]. However, previous studies also showed that the apoptosis-induced 
activity exerted by the natural plant extract or chemical compound is correlated with caspase-3 and 
caspase-9, but not caspase-8 [49,51,52] In the current study, the increase in cleaved caspase-3 and 
cleaved caspase-9 was verified by western blot compared with the control as cleaved caspase-8 was 
not found in BFTC cells after exposure to 13-acetoxysarcocrassolide. These results support the 
apoptosis-induced effects of 13-acetoxysarcocrassolide on BFTC cells displayed by flow cytometry 
and are in accordance with the evidence on caspase-3 and caspase-9-associated apoptosis shown 
previously [48–52]. Moreover, these data demonstrate that activation of caspase-3 and caspase-9 is 
likely involved in induction of apoptosis by 13-acetoxysarcocrassolide in BFTC cells.   
Heat shock proteins are a group of housekeeping molecules and function as chaperones to recognize 
proteins with abnormal structures against stress conditions [53]. A member of this group, heat shock 
protein 60 (HSP60) has been found to widely exist in nature and act as chaperones to increase cell 
survival under physiological stress circumstances [54]. In this study, the expression of HSP60 was 
reduced in BFTC cells treated with 13-acetoxysarcocrassolide. Investigations previously indicated that 
HSP60 expression was up-regulated in cervical cancer tissue [55]. This protein is a contributor to the 
development of human cervical cancer and has been suggested as a biomarker for the disease [55]. It 
has been reported that HSP60 and other proteins like Ku70 binding protein, alpha enolase, and 26S 
proteasome subunit were up-regulated in the E7 oncogene in HPV-negative cervical cancer cell line 
(C33A), suggesting that the up-regulation of HSP60 by E7 oncogene could be one of the essential 
factors associated with resistance of apoptosis [56]. Studies indicated that the exposure of tumor 
suppressors such as mitomycin C and IGFBP7 to cervical and colorectal carcinoma cells caused 
down-regulation of HSP60. The down-regulation of HSP60 is suggested as being partially responsible 
for an inhibitory effect in colorectal cancer [57,58]. It has been found that HSP60 is able to promote 
the activation of pro-caspase-3 during apoptosis in earlier investigations [38]. Moreover, since the 
siRNA knockdown of HSP60 was shown to induce both mitochondrial and p53-dependent apoptosis, 
HSP60 inhibitors have been indicated as potential anti-cancer agents [59]. The correlation between 
drug resistance and the level of HSP60 in cancer cells has been studied. The basal levels of HSP60 
were increased in cisplatin-resistant cervix squamous cell carcinoma cell subline A431/Pt than in 
non-resistant A431 cells [60]. In the current study, the down-regulation of HSP60 after treatment with 
13-acetoxysarcocrassolide is consistent with previous studies [57–60]. Also, the increased expression 
of cleaved caspase-3, cytochrome C and p53 exhibited by western blot further connects the potential 
major role of HSP60 with induction of apoptosis in BFTC cells. Thus, these data suggest  
that the reduction of HSP60 is one of the important contributors to the anti-tumor effects of 
13-acetoxysarcocrassolide and this is likely coupled with caspase-3, mitochondrial and p53-dependent 
apoptosis in BFTC cells. 
Both stress-70 protein and heat shock cognate 71 kDa protein (HSC71), which play important roles 
in tumorigenesis and apoptosis of cancer cells, were up-regulated in the current study. Stress-70 Mar. Drugs 2011, 9 2635 
 
protein acts as a chaperone involved in cell proliferation, differentiation, and tumorigenesis. The 
expression of Stress-70 protein greatly increased in pancreatic ductal carcinoma cells after treated with 
5-aza-2′-deoxycytidine, a strong suppressor of the cancer cells [61]. The expression of stress-70 
protein was also greatly elevated in erythroleukemia cells by radiation treatment. The over-expression 
of this protein was considered to be a relevant means of cell survival [62]. It has been reported that 
HSC71 is one of the most frequently found proteins in prostate cancer patients [63]. HSC71 was 
up-regulated in human neuroblastoma derived cells SH-SY5Y after treatment with staurosporine (STS), 
a broad spectrum protein kinase inhibitor and an extensively utilized apoptosis-inducer in the central 
nervous system [64]. In this study, the increased levels of stress-70 protein and HSC71 in BFTC cells 
treated with 13-acetoxysarcocrassolide suggest the association with the responses of either apoptosis or 
cell survival.   
Mutations of isocitrate dehydrogenase (IDH) gene have been identified in glioblastoma and were 
also investigated in thyroid cancer. Recently, the importance of IDH in anti-cancer therapeutics has 
been emphasized [65,66]. After administration with the chemotherapeutic agent from Withania 
somnifera along with paclitaxel, an effective chemical agent against lung cancer, significant up-regulation 
of the key enzymes in tricarboxylic acid (TCA) cycle such as IDH, succinate dehydrogenase, malate 
dehydrogenase, and alpha-ketoglutarate dehydrogenase was observed in lung cancer bearing animals, 
suggesting strong anti-tumor effects of the combination therapy [67]. Up-regulation of IDH1 has been 
correlated with the metastasis of human breast cancer [68]. Inhibition of IDH resulted in 
curcumin-induced apoptosis in the colon cancer cell line HCT116 [69]. Elevated expression of IDH in 
human esophageal squamous cell carcinoma has been reported [70]. A different alteration of this 
enzyme was reported in metastastic canine mammary carcinoma [71]. In this study, the 
down-regulation of IDH1 was observed by 2-DE analysis and verified by western blot analysis in 
BFTC cells treated with 13-acetoxysarcocrassolide. It suggested that the anti-cancer effects of 
13-acetoxysarcocrassolide may be correlated with its effect on TCA cycle in BFTC cells and 
associated with the reduction of IDH. 
The expressions of heterogeneous nuclear ribonucleoproteins (hnRNPs) in BFTC cells varied after 
treatment with 13-acetoxysarcocrassolide. It was found that hnRNP C1/C2 was greatly up-regulated, 
while hnRNP F was also up-regulated after the 13-acetoxysarcocrassolide treatment. HnRNP C1/C2 
takes part in mRNA transcript packaging, splicing, nuclear retention, and mRNA stability. It was 
suggested that these proteins are associated with DNA-damage responses and radiation-induced 
apoptosis [72]. Reports indicated that hnRNP F was greatly expressed in a number of tumor cells 
except in hepatocellular carcinoma. In tumor tissues, highly elevated expression of hnRNP F was 
observed in both nuclei and cytoplasma although it was expressed higher in the nuclei than in the 
cytoplasma [73]. The different regulation between hnRNP F and hnRNP H has been found in gastric 
carcinoma and hepatocellular carcinoma [73]. The results of our study also showed different regulation 
of hnRNP F and hnRNP H in BFTC cells after treatment with 13-acetoxysarcocrassolide. It implicates 
that down-regulation of hnRNP H could be associated with decreased nuclei in BFTC cells resulting 
from apoptosis induced by the treatment. Reports indicate that hnRNP F is a biomarker for colorectal 
cancer [74]. Based on the results of this study, hnRNP F is also suggested as a biomarker for bladder 
tumors. It has been shown that hnRNPs F/H plays an essential role in the production of Bcl-xS, 
apoptosis-promoted proteins in the Bcl-2 family. The addition of hnRNP F increases the production of Mar. Drugs 2011, 9 2636 
 
Bcl-xS and the knockdown of hnRNPs F/H by siRNAs decreases the ratio of Bcl-xS/BCL-xL [40]. 
The proteomic analysis and western blotting results of hnRNPs in this study showed up-regulation of 
both hnRNP C1/C2 and hnRNP F and down-regulation of hnRNP H while Bcl-xL expression was 
decreased after 13-acetoxysarcocrassolide treatment. These data suggest that the regulations of 
hnRNPs F/H and Bcl-xL were associated with the promotion of apoptosis induced by the treatment 
with 13-acetoxysarcocrassolide in BFTC cells.   
LDHB (l-lactate dehydrogenase B) is up-regulated after the 13-acetoxysarcocrassolide treatment. 
LDH release is an indicator of the integrity of cell membranes, since H2O2 treatment greatly elevates 
LDH level in normal cardiomyocytes [75]. The expression of LDHB was elevated in primary 
non-small cell lung cancer sera and progressively increased with increasing clinical stage. The level of 
LDHB also could be used to distinguish lung cancer from benign lung disease or healthy control 
groups with a sensitivity of 81%, a specificity of 70%, and a total accuracy of 76% [76]. It has been 
shown that the maintenance of low pyruvate level in colon cancer cells caused by the silencing of 
LDHB and the up-regulation of LDHA resulted in avoidance from cell death [77]. Increased 
expression of LDHB was also found in erythroleukemia cells treated with radiotherapy [62]. It is 
suggested that the up-regulation of LDHB in BFTC cells treated with 13-acetoxysarcocrassolide in the 
current study could be correlated with cytotoxic effects of 13-acetoxysarcocrassolide.  
The modulation of PDIA3 precursor and PPT1 in BFTC cells treated with 13-acetoxysarcocrassolide 
in the current study seems to present a paradigm shifting compared with some findings in previous 
reports. The functional roles of PDIA3 precursor in cells have been previously shown as a catalyst 
responsible for the rearrangement of disulphide bonds in the endoplasmic reticulum (ER) [78]. PDIA3 
was shown as a potential biomarker in ovarian cancer and prostate cancer. It was further suggested that 
the reduction of caspase activity resulted from a decrease of PDIA3 in prostate cancer cell 
lines [79,80]. On the other hand, PPT1 is an enzyme which contributes to deacylation of palmitoylated 
proteins. Overexpression of PPT1 resulted in a 200–350% increase in depalmitoylating activity and 
was associated with the decrease in cell death and resistance to apoptosis induced by chemotherapeutic 
agents like C2-ceramide or Adriamycin. It has been suggested that protein palmitoylation could be a 
physiological regulator of apoptosis in human neuroblastoma cells [81,82]. In this study, 
13-acetoxysarcocrassolide exhibited convincing evidence of anti-proliferation, anti-migration, and 
apoptosis-induction effects on BFTC cells in vitro. It is speculated that the down-regulation of PDIA3 
and the up-regulation of PPT1 in BFTC cells treated with 13-acetoxysarcocrassolide, which were 
observed by 2-DE analysis and verified by western blot analysis, may not affect the cytotoxic effects of 
13-acetoxysarcocrassolide on BFTC cells. Nevertheless, based on the results of study, PPT1 is a 
potential biomarker for bladder tumor. 
5. Conclusion 
In conclusion, combining the anti-proliferative, anti-migratory and apoptosis-induced results of 
13-acetoxysarcocrassolide, we conclude that this cembranoid isolated from the Formosan soft coral 
exerted cytotoxic effects on bladder female transitional cancer (BFTC) cells in vitro. The regulation of 
critical proteins such as HSP60, HSC71, stress-70 protein, IDH, hnRNP C1/C2, hnRNP F, hnRNP H, 
and LDHB after 13-acetoxysarcocrassolide treatment, revealed by 2-DE, LC-MS/MS and western blot, Mar. Drugs 2011, 9 2637 
 
suggested that these proteins are likely important biomarkers and may play major roles in the induction 
of apoptosis or the influence on energy metabolism in bladder transitional carcinoma. More noteworthy 
is that PPT1 and hnRNP F could be new biomarkers for bladder cancer. Furthermore, regarding 
modulation of HSP60 and hnRNPs F/H, up-regulation of cleaved caspase-3, cleaved caspase-9, 
cytochrome C, p53 as well as down-regulation of Bcl-xL, further demonstrates that the cytotoxic 
effects of 13-acetoxysarcocrassolide on BFTC cells are correlated with these pro-apoptotic factors. 
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